DREAM, a possible answer to the estrogen paradox of the Women's Health Initiative Trial.
Breast cancer
DREAM
Estrogen
Hormone therapy
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
12
09
2021
revised:
21
11
2021
accepted:
21
12
2021
entrez:
14
1
2022
pubmed:
15
1
2022
medline:
15
1
2022
Statut:
epublish
Résumé
Estrogen is thought to cause proliferation of all estrogen receptor positive (ER+) breast cancers. Paradoxically, in the Women's Health Initiative Trial, estrogen-only hormone replacement therapy reduced the incidence and mortality of low grade, ER+, HER2- breast cancer. We gave estradiol to 19 post-menopausal women with newly diagnosed low-grade, ER+, HER2- breast cancer in a prospective window of opportunity clinical trial and examined the changes in proliferation and gene expression before and after estradiol treatment. Ki67 decreased in 13/19 (68%) patients and 8/13 (62%) showed a decrease in Risk of Recurrence Score. We chose three prototypical estrogen responders (greatest decrease in ROR) and non-responders (no/minimal change in ROR) and applied a differential gene expression analysis to develop pre-treatment (PRESTO-30
Identifiants
pubmed: 35028452
doi: 10.1016/j.heliyon.2021.e08666
pii: S2405-8440(21)02769-9
pmc: PMC8741439
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e08666Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Clin Endocrinol Metab. 2021 Jun 16;106(7):1929-1955
pubmed: 33755733
JAMA. 2020 Jul 28;324(4):369-380
pubmed: 32721007
Endocr Relat Cancer. 2015 Feb;22(1):R1-31
pubmed: 25339261
Lancet. 2013 Mar 9;381(9869):805-16
pubmed: 23219286
Breast Cancer Res Treat. 2013 Nov;142(2):237-55
pubmed: 24162158
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Appl Immunohistochem Mol Morphol. 2017 Nov/Dec;25(10):687-695
pubmed: 27093453
N Engl J Med. 2020 Dec 24;383(26):2557-2570
pubmed: 33369357
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Nat Rev Mol Cell Biol. 2013 Jun;14(6):329-40
pubmed: 23698583
Nucleic Acids Res. 2019 Sep 26;47(17):9087-9103
pubmed: 31400114
Mol Endocrinol. 2000 May;14(5):753-60
pubmed: 10809237
J Clin Oncol. 2014 Jul 20;32(21):2255-69
pubmed: 24868023
J Natl Cancer Inst. 2006 Feb 15;98(4):262-72
pubmed: 16478745
Breast Cancer Res. 2021 Sep 27;23(1):92
pubmed: 34579745
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Am J Surg Pathol. 1986 Jun;10(6):382-93
pubmed: 3717495
Oncogene. 2019 Feb;38(7):1080-1092
pubmed: 30206359
JAMA. 2009 Aug 19;302(7):774-80
pubmed: 19690310
J Cell Physiol. 2010 Jul;224(1):28-32
pubmed: 20301197
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nucleic Acids Res. 2016 Jul 8;44(W1):W3-W10
pubmed: 27137889
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
JNCI Cancer Spectr. 2018 May 22;2(2):pky005
pubmed: 31360844
Breast Cancer Res. 2019 Dec 31;22(1):2
pubmed: 31892336
Nat Rev Clin Oncol. 2012 Feb 28;9(4):223-9
pubmed: 22371132
Nucleic Acids Res. 2018 Jan 4;46(D1):D794-D801
pubmed: 29126249
PLoS One. 2012;7(11):e49359
pubmed: 23166647
Breast Cancer Res Treat. 1999 Mar;54(2):117-22
pubmed: 10424402
Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18879-86
pubmed: 22011582
Lancet. 2005 Feb 19-25;365(9460):671-9
pubmed: 15721472
Annu Rev Genet. 2021 Nov 23;55:309-329
pubmed: 34496610
J Clin Oncol. 2010 Sep 20;28(27):4111-9
pubmed: 20697068
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
PLoS Comput Biol. 2011 Oct;7(10):e1002240
pubmed: 22028643
Mod Pathol. 2002 Dec;15(12):1348-56
pubmed: 12481017
Cancer Res. 1990 Jun 15;50(12):3545-50
pubmed: 2187598
Oncogene. 2010 May 20;29(20):2983-95
pubmed: 20208560
Cell Death Differ. 2021 Dec;28(12):3357-3370
pubmed: 34183782
J Biol Chem. 1998 Apr 24;273(17):10696-701
pubmed: 9553133
J Am Med Assoc. 1960 Mar 19;172:1288-9
pubmed: 14419312